Maze Therapeutics, Inc. SEC filings MAZE
Maze Therapeutics, Inc. has 222 filings in SEC EDGAR's recent list, going back to Jun 21, 2024. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 16, 2026 (material agreement, unregistered share sale). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 16, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 17, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2026 | Jun 8, 2026 |
| 8-K |
Current report
Officer or director change
|
May 22, 2026 | May 18, 2026 |
| EFFECT | Filing | May 13, 2026 | — |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
| POS AM | Filing | May 12, 2026 | — |
| ARS | Annual report to shareholders | Apr 28, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Jun 8, 2026 |
| 8-K |
Current report
Other events
|
Apr 22, 2026 | Apr 21, 2026 |
| 424B5 | Prospectus supplement | Apr 22, 2026 | — |
| 10-K | Annual report | Mar 25, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations, Officer or director change, Regulation FD disclosure
|
Mar 25, 2026 | Mar 24, 2026 |
| S-8 | Employee stock plan registration | Feb 4, 2026 | — |
| S-3ASR | Automatic shelf registration | Feb 4, 2026 | — |
| 8-K |
Current report
Material agreement, Agreement ended, New debt
|
Feb 4, 2026 | Feb 2, 2026 |
| 10-Q | Quarterly report | Nov 6, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 424B3 | Prospectus | Nov 6, 2025 | — |
| S-1 | Registration statement | Oct 17, 2025 | — |
| 8-K |
Current report
Officer or director change
|
Oct 6, 2025 | Oct 6, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Sep 11, 2025 | Sep 10, 2025 |
| 8-K |
Current report
Officer or director change
|
Sep 2, 2025 | Sep 2, 2025 |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2025 | Aug 12, 2025 |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 14, 2025 | May 14, 2025 |
| 10-K | Annual report | Mar 31, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 31, 2025 | Mar 31, 2025 |
| SEC STAFF LETTER | Filing | Feb 6, 2025 | — |
| S-8 | Employee stock plan registration | Jan 31, 2025 | — |
| 424B4 | Prospectus | Jan 31, 2025 | — |
| EFFECT | Filing | Jan 30, 2025 | — |
| S-1MEF | Filing | Jan 30, 2025 | — |
| CERT | Filing | Jan 30, 2025 | — |
| CORRESP | Letter to the SEC | Jan 30, 2025 | — |
| S-1/A | Amended registration statement | Jan 30, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 29, 2025 | — |
| CORRESP | Letter to the SEC | Jan 28, 2025 | — |
| CORRESP | Letter to the SEC | Jan 28, 2025 | — |
| 8-A12B | Filing | Jan 27, 2025 | — |
| S-1/A | Amended registration statement | Jan 27, 2025 | — |
| CORRESP | Letter to the SEC | Jan 21, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 15, 2025 | — |
| CORRESP | Letter to the SEC | Jan 10, 2025 | — |
| CORRESP | Letter to the SEC | Jan 7, 2025 | — |
| S-1 | Registration statement | Jan 7, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 13, 2024 | — |
| DRS/A | Filing | Dec 6, 2024 | — |
| DRSLTR | Filing | Sep 13, 2024 | — |
| DRS/A | Filing | Sep 13, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 26, 2024 | — |
| DRSLTR | Filing | Aug 15, 2024 | — |
| DRS/A | Filing | Aug 15, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 8, 2024 | — |
| DRSLTR | Filing | Jul 31, 2024 | — |
| DRS/A | Filing | Jul 31, 2024 | — |
| SEC STAFF LETTER | Filing | Jul 30, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 25, 2024 | — |
| DRS | Filing | Jun 21, 2024 | — |
Showing 64 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- MAZE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1842295
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.